CRISPR Therapeutics AG — Director's Dealing 2019

Mar 7, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2019-03-05

Reporting Person: Ho Tony W (See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-05	Restricted Stock Units	A	10000	$40.87	Acquired	32869	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-05	Stock Option (Right to Buy)	$40.87	A	75000	Acquired	2029-03-05	Common Shares (75000)	Direct

Footnotes

F1: This restricted stock unit award was granted on March 5, 2019 with respect to 10,000 Common Shares, with (i) 3,333 shares vesting on March 5, 2020, (ii) 3,333 shares vesting on March 5, 2021, and (iii) 3,334 shares vesting on March 5, 2022. Each restricted stock unit represents a contingent right to receive one CRSP Common Share.

F2: This option was granted on March 5, 2019 with respect to 75,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 5, 2019.